Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Hematology
•
Internal Medicine
Would you use methotrexate to treat a small T-LGL clone (<650 cells/m3), with mild pancytopenia, and associated autoimmune disease such as systemic sclerosis?
Would a better alternative be consideration of a clinical trial with ruxolitinib?
Related Questions
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
In pure red cell aplasia, does peripheral blood-positive IgG for parvovirus have significance if persistently positive on retesting, but IgM and PCR are negative?
What parameters would you use to monitor and interpret iron levels in a hemochromatosis patient where ferritin is unreliable due to underlying chronic inflammation?
How would you manage a healthy 31 younger patient with nodular lymphocyte predominant Hodgkin lymphoma with severe hemolytic anemia but no other symptoms that responded to steroids?
What is your approach to managing follicular lymphoma with central nervous system involvement?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
How would you treat severe, symptomatic splenomegaly in a patient with ET/MF who has progressed through all approved JAK inhibitors and is not a candidate for alloSCT?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What is the consensus on giving Pemivibart for Pre-Exposure COVID prophylaxis in immunocompromised patients?